No products in the cart.
Cat:GMP-h-LN
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Liver diseases (muscular dystrophy, lethal
skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome) and related syndrome. GeneMedi offers paired diagnostics grade laminins (LN) antibodies (monoclonal antibody, mab) and antigens for Liver diseases (muscular dystrophy, lethal
skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome) rapid test kit of laminins (LN) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Liver diseases (muscular dystrophy, lethal
skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.laminins?are high-molecular weight?(~400 to ~900 kDa) proteins of the?extracellular matrix. They are a major component of the?basal lamina?(one of the layers of the?basement membrane), a protein network foundation for most cells and organs. The laminins are an important and biologically active part of the basal lamina, influencing cell differentiation, migration, and adhesion.[1][2]
Product Description
Cat No. of Pruducts
GMP-h-LN-Ag01:Recombinant Human LN Protein
Product Name
Recombinant Human LN Protein
Target
laminins
Alias of Target/Biomarker
#N/A
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
laminins (LN) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in LN level test of Liver diseases (muscular dystrophy, lethal
skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome) and related syndrome evaluation
Tag
His
Products description
Recombinant Human LN Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-LN-Ab01,GMP-h-LN-Ab02:Anti-Human LN mouse monoclonal antibody (mAb)
Product Name
Anti-Human LN mouse monoclonal antibody (mAb)
Target
laminins (LN)
Alias of Target/Biomarker
#N/A
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human laminins (LN) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other laminins (LN) antibodies in LN level test of Liver diseases (muscular dystrophy, lethal
skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome) and related syndrome evaluation.
Tag
mFc
Products description
Anti-Human LN mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other laminins (LN) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
